Transgene and NEC report 100% three-year disease-free survival
Transgene (TNG) and NEC (6701) said they report 100% three-year disease-free survival with TG4050 and plan to publish Phase 1 results in Nature Communications.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Transgene and Nec report 100% three-year disease-free survival with TG4050
Transgene and Nec say TG4050 showed 100% three-year disease-free survival, with a Nature Communications peer-reviewed publication highlighting Phase 1 clinical and translational findings and durable neoantigen-specific T cell responses.